GW Pharmaceuticals

(NASDAQ: GWPH)
Healthcare  |  Drug Manufacturers—General
102.88 0.0 0.0%
Stock Price | Dec. 11, 2019, 4 p.m.
14 Followers
Bid: 0.0
Ask: 0.0
Prev. Close: 102.88
52 Week Low: 90.14
52 Week High: 196.0
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. Its business activities are functioned through three reportable segments which are Commercial, Sativex Research and Development and Pipeline Research and Development. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

Read more Read less

Recently Viewed Tickers

Premium Cannabis Stocks Review - Pre-Market Edition 12/10/19

15 Comments
2 days ago

Premium Cannabis Stocks Review - Weekend Edition 12/09/19

23 Comments
4 days ago

Premium Cannabis Stocks Review - Pre-Market Edition 12/05/19

10 Comments
1 week ago

Premium Cannabis Stocks Review - Weekend Edition 12/02/19

44 Comments
1 week ago

Premium Cannabis Stocks Review - Weekend Edition 11/25/19

24 Comments
2 weeks ago

Premium Cannabis Stocks Review - Pre-Market Edition 11/21/19

25 Comments
3 weeks ago

Premium Cannabis Stocks Review - Pre-Market Edition 11/19/19

11 Comments
3 weeks ago

Premium Cannabis Stocks Review - AM Edition 11/18/19

7 Comments
3 weeks ago

Premium Cannabis Stocks Review - Weekend Edition 11/18/19

7 Comments
3 weeks ago

Premium ​Weekly Review 11/15/19

3 weeks ago